EGFR and adenocarcinoma: The RB1 alteration in this patient was found on repeat biopsy at the time of progression on first generation EGFR tyrosine kinase inhibitor (TKI), along with an acquired EGFR T790M mutation and a histopathology of adenocarcinoma.